Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's drugs
Pharma
EMA changes tune, endorses Leqembi with restriction
After a prior rejection, the EMA now recommends an approval to Leqembi, but only in mild Alzheimer's patients with one or no copy of the ApoE4 gene.
Angus Liu
Nov 14, 2024 12:10pm
Suboptimal Leqembi vials could create millions in waste: study
Oct 14, 2024 3:00pm
Eisai, Biogen's Leqembi nabs UK nod but not reimbursement
Aug 22, 2024 9:23am
Biogen retains biosimilars as Leqembi plows ahead
Aug 1, 2024 10:15am
Game on: Lilly's Alzheimer's drug Kisunla gains FDA nod
Jul 2, 2024 2:33pm
Eisai, Biogen's subQ Leqembi delayed amid FDA's data request
Apr 1, 2024 10:45am
